|
English
|
正體中文
|
简体中文
|
2828323
|
|
???header.visitor??? :
32275304
???header.onlineuser??? :
1823
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"gandossi e"???jsp.browse.items-by-author.description???
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 中山醫學大學 |
2021 |
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation
|
Park, K; Chang, GC; Curigliano, G; Lim, WT; Soo, RA; Molina-Vila, MA; Cattan, V; Darville, H; Gandossi, E; Smutna, V; Sudey, I; Viteri, S |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation
|
Viteri S; Chang G.-C; Chiari R; Cho B.C; Ciardiello F; Curigliano G; Hida T; Lee D.H; Lim W.T.D; Chia-Chi Lin; Martinez A; Murakami H; Natsume I; Nishio M; Paz-Ares L; Soo R.A; Cattan V; Gandossi E; Heck H; Park K. |
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
